...Acerus (formerly Trimel Pharmaceuticals Corp. ) granted Aytu exclusive, U.S. marketing rights to testosterone replacement therapy Natesto testosterone...

...at US Oncology Inc. , which was acquired by McKesson Corp. (NYSE:MCK). Drug delivery company Trimel Pharmaceuticals Corp....

...$199 for one dispenser. Last year, Endo acquired U.S. and Mexican rights to Natesto from Trimel Pharmaceuticals Corp....

...from Trimel to commercialize Natesto in the U.S. and Mexico (see BioCentury, Dec. 15, 2014). Trimel Pharmaceuticals Corp....

...collaborate with Trimel on clinical development and regulatory activities for Natesto (see BioCentury, June 2). Trimel Pharmaceuticals Corp....

...Osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis, tendonitis, bursitis and acute gout ü Natesto testosterone Trimel Pharmaceuticals Corp....

...after it completes its analysis of the data, but did not disclose a time frame. Trimel Pharmaceuticals Corp....

...NYSE:GSK) EC approves Anoro umeclidinium/vilanterol as a once-daily maintenance bronchodilator to relieve symptoms in COPD Trimel Pharmaceuticals Corp....

...in chronic kidney disease (CKD) patients receiving hemodialysis. The PDUFA date is Jan. 24, 2015. Trimel Pharmaceuticals Corp....

...the bioadhesive intranasal gel formulation of testosterone to reflect thrice-daily dosing (see BioCentury, Jan. 20). Trimel Pharmaceuticals Corp....